Health and Healthcare

Monday's Top Biotech and Medical Stocks

From BioHealth Investor

Biotechnology

HEMOBIOTECH INC [HMBT.OB] +9.52%
AFFYMAX, INC. [AFFY] +7.03%
OSIRIS THERAPEUTICS [OSIR] +6.93%
IDM PHARMA INC [IDMI] +6.53% 0
BIOCRYST PHARM INC [BCRX] +6.23%

Diagnostic Substances

GENELABS TECH INC [GNLB] +6.00%
PONIARD PHARMA [PARD] +5.57%
AVALON PHARMACEUTIC [AVRX] +4.16%
AVIGEN INC [AVGN] +3.07%
IMMUCELL CP [ICCC] +2.80%

Drug Delivery

NOVADEL PHARMA INC [NVD] +3.27%
GENEREX BIOTECH CORP [GNBT] +2.86%
PETMED EXPRESS INC [PETS] +2.12%
FLAMEL TECH SA ADR [FLML] +1.71%
BENTLEY PHARMACEUTIC [BNT] +1.42%

Drug Manufacturers

ACCESS PHARMACEUTICL [ACCP.OB] +37.98%
SINOVAC BIOTECH LTD [SVA] +7.84%
EXEGENICS INC [EXEG.OB] +7.14%
ATHEROGENICS INC [AGIX] +7.07%
NEXMED INC [NEXM] +6.43%

Medical Appliances & Equipment

LANGER INC [GAIT] +10.84%
MEDIS TECH LTD [MDTL] +7.61%
THERAGENICS CORP [TGX] +4.90%
ARRHYTHMIA RES TECH [HRT] +4.62%
CYBERONICS INC [CYBX] +4.45%

Medical Instruments & Supplies

IMMUNOCELLULAR THERA [IMUC.OB] +10.00%
BIOMIMETIC THERAPEUT [BMTI] +9.01%
DTLL INC [DTLI.OB] +4.55%
CHINA MEDICAL TECH [CMED] +3.98%
CARDIAC SCIENCE CORP [CSCX] +3.91%

Medical Laboratories & Research

MEDASORB TECHNOLOGS [MSBT.OB] +12.00% $0
BIO-IMAGING TECH [BITI] +3.97% $33.5 M
OSI PHARMACEUTIC [OSIP] +1.99% $2.0 B
RADNET INC [RDNT.OB] +1.37% $0
ENZO BIOCHEM INC [ENZ] +1.26%

http://www.biohealthinvestor.com/

Take This Retirement Quiz To Get Matched With A Financial Advisor (Sponsored)

Take the quiz below to get matched with a financial advisor today.

Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests.

Here’s how it works:
1. Answer SmartAsset advisor match quiz
2. Review your pre-screened matches at your leisure. Check out the advisors’ profiles.
3. Speak with advisors at no cost to you. Have an introductory call on the phone or introduction in person and choose whom to work with in the future

Take the retirement quiz right here.

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.